FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016013570> ?p ?o ?g. }

• W2016013570 abstract "INTRODUCTION : Multiple trastuzumab-containing (neo)adjuvant regimens are used for HER2+ BrCa, but the experience with these regimens in routine practice is not reported. Some oncologists select TCH based on BCIRG 006, whereas others prefer anthracycline-based therapy. We evaluated whether oncologists’ perceptions of these regimens match clinical experience. METHODS : We surveyed 151 Wisconsin (WI) oncologists regarding factors impacting selection of TCH versus AC-TH; 65 (42%) responded. At the same time, we reviewed 200 cases of HER2+ BrCa treated with adjuvant trastuzumab from 2003 to 2010 at the University of Wisconsin Carbone Cancer Center (UW) and the Marshfield Clinic. We collected baseline patient and tumor characteristics, regimen administered, and toxicities as assessed by lab values, cardiac ejection fraction (EF), hospitalizations, dose reductions/delays, and ability to complete therapy. RESULTS : Two-thirds of surveyed oncologists prefer anthracycline-based therapy over TCH. Of oncologists preferring TCH, 20 of 23 had been in practice for >10 years. Oncologists perceived that AC-TH and TCH were equally likely to be completed. The majority of physicians select therapy based on patient age and stage, with a preference for AC-TH for node-positive disease and TCH for early stage (T1a-bN0) tumors. Despite BCIRG 006 remaining unpublished at the time of the survey, peer-review publication was cited as the most important factor in selecting this regimen. Although use of granulocyte colony stimulating factor (GCSF) in BCIRG 006 has not reported, 50% of oncologists indicated routine use with cycle 1 of TCH. Of the 200 cases reviewed, 114 women received AC-TH, 48 women received TCH, and 38 had other regimens. The median age was 53 years old, 52% had node positive disease. Acute toxicity trended higher with TCH. For example, there were fewer dose modifications/delays for AC-TH than TCH (31% vs. 46%, p=0.07). This may have been due to common use of GCSF with AC-TH (77% vs. 33% use with TCH). Neutropenic fever (NF) was higher with TCH, reaching 25% incidence when administered without GCSF. However, NF did not occur in the 8 TCH patients who received cycle 1 GCSF. There was no correlation between NF and patient age. The incidence of left ventricular EF decline leading to cessation of trastuzumab was similar for both regimens (19.4% AC-TH vs. 14.6% TCH; p = 0.64). Trastuzumab was completed as planned in 70% of patients. Although EF decline was most common explanation, 13% of early trastuzumab discontinuations occurred for other reasons. CONCLUSION : TCH and AC-TH are the most commonly administered adjuvant regimens for WI women with HER2+ BrCa. Amongst WI oncologists, TCH is perceived as safer, but is less likely to be recommended for node-positive BrCa. This retrospective analysis suggests that acute myelosuppression is greater for TCH, with a significant rate of NF. Per ASCO guidelines, these data suggest GCSF should be used routinely with TCH due to high rate of FN. We were intrigued that oncologists who have been in practice longer are more likely to choose TCH. The reasons for this are unclear, but are perhaps related to prior experience with long-term cardiotoxicity with AC-TH. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-12." @default.
• W2016013570 created "2016-06-24" @default.
• W2016013570 creator A5003340711 @default.
• W2016013570 creator A5006752355 @default.
• W2016013570 creator A5011365544 @default.
• W2016013570 creator A5011579642 @default.
• W2016013570 creator A5029241146 @default.
• W2016013570 creator A5036573429 @default.
• W2016013570 creator A5053681266 @default.
• W2016013570 creator A5074072485 @default.
• W2016013570 creator A5076344697 @default.
• W2016013570 creator A5079186626 @default.
• W2016013570 creator A5081595816 @default.
• W2016013570 creator A5087910578 @default.
• W2016013570 date "2011-12-15" @default.
• W2016013570 modified "2023-09-27" @default.
• W2016013570 title "P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin." @default.
• W2016013570 doi "https://doi.org/10.1158/0008-5472.sabcs11-p5-18-12" @default.
• W2016013570 hasPublicationYear "2011" @default.
• W2016013570 type Work @default.
• W2016013570 sameAs 2016013570 @default.
• W2016013570 citedByCount "0" @default.
• W2016013570 crossrefType "proceedings-article" @default.
• W2016013570 hasAuthorship W2016013570A5003340711 @default.
• W2016013570 hasAuthorship W2016013570A5006752355 @default.
• W2016013570 hasAuthorship W2016013570A5011365544 @default.
• W2016013570 hasAuthorship W2016013570A5011579642 @default.
• W2016013570 hasAuthorship W2016013570A5029241146 @default.
• W2016013570 hasAuthorship W2016013570A5036573429 @default.
• W2016013570 hasAuthorship W2016013570A5053681266 @default.
• W2016013570 hasAuthorship W2016013570A5074072485 @default.
• W2016013570 hasAuthorship W2016013570A5076344697 @default.
• W2016013570 hasAuthorship W2016013570A5079186626 @default.
• W2016013570 hasAuthorship W2016013570A5081595816 @default.
• W2016013570 hasAuthorship W2016013570A5087910578 @default.
• W2016013570 hasConcept C121608353 @default.
• W2016013570 hasConcept C126322002 @default.
• W2016013570 hasConcept C143998085 @default.
• W2016013570 hasConcept C146357865 @default.
• W2016013570 hasConcept C151730666 @default.
• W2016013570 hasConcept C2776802502 @default.
• W2016013570 hasConcept C2777982462 @default.
• W2016013570 hasConcept C2779786085 @default.
• W2016013570 hasConcept C2781413609 @default.
• W2016013570 hasConcept C512399662 @default.
• W2016013570 hasConcept C530470458 @default.
• W2016013570 hasConcept C71924100 @default.
• W2016013570 hasConcept C86803240 @default.
• W2016013570 hasConceptScore W2016013570C121608353 @default.
• W2016013570 hasConceptScore W2016013570C126322002 @default.
• W2016013570 hasConceptScore W2016013570C143998085 @default.
• W2016013570 hasConceptScore W2016013570C146357865 @default.
• W2016013570 hasConceptScore W2016013570C151730666 @default.
• W2016013570 hasConceptScore W2016013570C2776802502 @default.
• W2016013570 hasConceptScore W2016013570C2777982462 @default.
• W2016013570 hasConceptScore W2016013570C2779786085 @default.
• W2016013570 hasConceptScore W2016013570C2781413609 @default.
• W2016013570 hasConceptScore W2016013570C512399662 @default.
• W2016013570 hasConceptScore W2016013570C530470458 @default.
• W2016013570 hasConceptScore W2016013570C71924100 @default.
• W2016013570 hasConceptScore W2016013570C86803240 @default.
• W2016013570 hasLocation W20160135701 @default.
• W2016013570 hasOpenAccess W2016013570 @default.
• W2016013570 hasPrimaryLocation W20160135701 @default.
• W2016013570 hasRelatedWork W1604277535 @default.
• W2016013570 hasRelatedWork W1925211454 @default.
• W2016013570 hasRelatedWork W2026783022 @default.
• W2016013570 hasRelatedWork W2029735288 @default.
• W2016013570 hasRelatedWork W2087791626 @default.
• W2016013570 hasRelatedWork W2112335800 @default.
• W2016013570 hasRelatedWork W2124845354 @default.
• W2016013570 hasRelatedWork W2164642064 @default.
• W2016013570 hasRelatedWork W2169307670 @default.
• W2016013570 hasRelatedWork W2313437566 @default.
• W2016013570 hasRelatedWork W2427690842 @default.
• W2016013570 hasRelatedWork W2738336818 @default.
• W2016013570 hasRelatedWork W2783139623 @default.
• W2016013570 hasRelatedWork W2783200533 @default.
• W2016013570 hasRelatedWork W2796208006 @default.
• W2016013570 hasRelatedWork W3081807968 @default.
• W2016013570 hasRelatedWork W3081892489 @default.
• W2016013570 hasRelatedWork W3129805563 @default.
• W2016013570 hasRelatedWork W3136458548 @default.
• W2016013570 hasRelatedWork W2186012755 @default.
• W2016013570 isParatext "false" @default.
• W2016013570 isRetracted "false" @default.
• W2016013570 magId "2016013570" @default.
• W2016013570 workType "article" @default.